Skip to main content
. Author manuscript; available in PMC: 2014 Jun 13.
Published in final edited form as: J Drug Target. 2013 Sep 30;21(10):904–913. doi: 10.3109/1061186X.2013.837469

FIGURE 2. Accumulation of siRNA with DOPC nanoliposomes in vivo.

FIGURE 2

Fluorescent (A) and phase (B) view of liposomes after siRNA incorporation.

C. Hematoxylin &Eosin stain of HeyA8 ovarian tumor.

D. Autofluorescence in tumor 48 hours after intravenous administration of nonfluorescent control siRNA.

E. Tumor accumulation of Alexa 555 siRNA (red fluoresce) incorporated in DOPC.

F. Alexa 555 siRNA is seen in both tumor cells and surrounding macrophages (green) (Landen et al., 2005).

LANDEN, C. N., CHAVEZ-REYES, A., BUCANA, C., SCHMANDT, R., DEAVERS, M. T., LOPEZ-BERESTEIN, G. & SOOD, A. K. 2005. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer research, 65, 6910–6918.